C WorldWide Group Holding A S Increases Stake in PROCEPT BioRobotics Corporation $PRCT

C WorldWide Group Holding A S increased its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 150.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 375,000 shares of the company’s stock after buying an additional 225,000 shares during the period. C WorldWide Group Holding A S’s holdings in PROCEPT BioRobotics were worth $11,798,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. US Bancorp DE increased its stake in shares of PROCEPT BioRobotics by 175.7% during the third quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after buying an additional 1,079 shares during the period. Lazard Asset Management LLC increased its stake in shares of PROCEPT BioRobotics by 90.7% during the second quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock valued at $98,000 after buying an additional 810 shares during the period. Osaic Holdings Inc. increased its stake in shares of PROCEPT BioRobotics by 20.3% during the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after buying an additional 337 shares during the period. IFP Advisors Inc increased its stake in shares of PROCEPT BioRobotics by 24.0% during the third quarter. IFP Advisors Inc now owns 5,024 shares of the company’s stock valued at $179,000 after buying an additional 974 shares during the period. Finally, Inceptionr LLC purchased a new position in shares of PROCEPT BioRobotics during the third quarter valued at $212,000. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, Director Antal Rohit Desai purchased 98,699 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were acquired at an average price of $24.55 per share, for a total transaction of $2,423,060.45. Following the completion of the purchase, the director owned 426,262 shares of the company’s stock, valued at approximately $10,464,732.10. The trade was a 30.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Alaleh Nouri sold 5,363 shares of the business’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $25.96, for a total value of $139,223.48. Following the sale, the executive vice president owned 105,354 shares in the company, valued at $2,734,989.84. The trade was a 4.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have acquired 426,262 shares of company stock worth $10,483,091 and have sold 23,229 shares worth $573,466. Insiders own 17.40% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PRCT. Leerink Partners cut their price target on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Piper Sandler reiterated an “overweight” rating and issued a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Tuesday, April 21st. Oppenheimer reiterated a “market perform” rating on shares of PROCEPT BioRobotics in a research note on Thursday, February 26th. Finally, Wall Street Zen upgraded PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, PROCEPT BioRobotics currently has a consensus rating of “Hold” and an average price target of $41.45.

PROCEPT BioRobotics Price Performance

PRCT opened at $25.40 on Monday. The business’s 50-day moving average is $25.06 and its two-hundred day moving average is $29.29. PROCEPT BioRobotics Corporation has a 1 year low of $19.35 and a 1 year high of $66.85. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The firm has a market capitalization of $1.45 billion, a PE ratio of -13.96 and a beta of 0.83.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). The company had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $80.52 million. PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. PROCEPT BioRobotics’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.45) EPS. Research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.